Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537518 | 1.00 | ALPL (0.45) | ALPLAAK1MAPTCASP1AURKA | |
| SCHEMBL22447737 | 0.90 | ALPL (0.39) | ALPLAAK1MAPTCASP1AURKA | |
| SCHEMBL25778306 | 0.89 | ALPL (0.39) | ALPLAAK1MAPTCASP1AURKA | |
| SCHEMBL1118850 | 0.87 | MAPT (0.40) | ALPLAAK1MAPTCASP1AURKA | |
| SCHEMBL462679 | 0.85 | AAK1 (0.47) | ALPLAAK1MAPTPDGFRBKDR | |
| SCHEMBL13975916 | 0.84 | AAK1 (0.46) | ALPLAAK1PDGFRBKDRDGAT1 | |
| SCHEMBL3668559 | 0.83 | ALPL (0.46) | ALPLAAK1PDGFRBKDRDGAT1 | |
| SCHEMBL29504617 | 0.83 | ALPL (0.46) | ALPLAAK1PDGFRBKDRDGAT1 | |
| SCHEMBL29555798 | 0.83 | ALPL (0.46) | ALPLAAK1PDGFRBKDRDGAT1 | |
| SCHEMBL407919 | 0.83 | ALPL (0.46) | ALPLAAK1PDGFRBKDRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436952-A | Synthesis method of 2-methoxy-3-amino-5-pyridine boronic acid pinacol ester and intermediate thereof | 杭州珠联医药科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240316022-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024086296-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| EP-2079726-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008033857-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1831168-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | Vertex Pharmaceuticals Incorporated (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-17 | — | — | US | disclosed |
| WO-2006065946-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ALPL 4315/4885AAK1 299/4885MAPT 2358/4885 |
| US-20240316022-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | ALPL 3517/4885AAK1 1349/4885MAPT 1775/4885 |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | ALPL 1811/4885AAK1 1867/4885MAPT 1365/4885 |
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | ALPL 3579/4885AAK1 236/4885MAPT 1299/4885 |
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | ALPL 2558/4885AAK1 2552/4885MAPT 233/4885 |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | ALPL 2971/4885AAK1 1688/4885MAPT 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.